Appendix 3B

New issue announcement,
application for quotation of additional securities
and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.


Name of entity

| Neuren Pharmaceuticals Limited |

ABN

| 111 496 130 |

We (the entity) give ASX the following information.

**Part 1 - All issues**

*You must complete the relevant sections (attach sheets if there is not enough space).*

<table>
<thead>
<tr>
<th>1</th>
<th>Class of securities issued or to be issued</th>
<th>Ordinary Shares</th>
</tr>
</thead>
</table>

| 2 | Number of securities issued or to be issued (if known) or maximum number which may be issued | 25,625,000 |

| 3 | Principal terms of the securities (eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion) | Pari passu with existing ordinary shares |

+ See chapter 19 for defined terms.
4 Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?

If the additional securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes

5 Issue price or consideration

A$0.08 per share (or the NZ$ equivalent under the Share Purchase Plan)

6 Purpose of the issue

To meet working capital requirements and the development and reporting of top level results for the Phase 3 clinical trial of Glypromate®

7 Dates of entering securities into uncertificated holdings or despatch of certificates

30 September 2008

8 Number and class of all securities quoted on ASX (including the securities in clause 2 if applicable)

<table>
<thead>
<tr>
<th>Number</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>257,464,313</td>
<td>Ordinary Shares</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
Neuren Pharmaceuticals Limited
ARBN 111 496 130

Appendix 3B
New issue announcement

| Number | “Class
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1,800,000</td>
<td>Ordinary Share Options exercisable at A$0.60 before 1 December 2008</td>
</tr>
<tr>
<td>17,517,627</td>
<td>Ordinary Share Options exercisable at NZ$0.392 before 31 March 2009</td>
</tr>
<tr>
<td>720,000</td>
<td>Ordinary Share Options exercisable at NZ$0.392 before 31 March 2010</td>
</tr>
<tr>
<td>600,000</td>
<td>Ordinary Share Options exercisable at NZ$0.472 before 31 March 2010</td>
</tr>
<tr>
<td>3,000,000</td>
<td>Ordinary Share Options exercisable at A$0.25 before 7 February 2011</td>
</tr>
</tbody>
</table>

9 Number and “class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) Not applicable

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required? Not applicable

12 Is the issue renounceable or non-renounceable? Not applicable

13 Ratio in which the “securities will be offered Not applicable

14 “Class of “securities to which the offer relates Not applicable

15 “Record date to determine entitlements Not applicable

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? Not applicable

17 Policy for deciding entitlements in relation to fractions Not applicable

+ See chapter 19 for defined terms.
<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Names of countries in which the entity has ‘security holders who will not be sent new issue documents</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>Note: Security holders must be told how their entitlements are to be dealt with.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cross reference: rule 7.7.</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Closing date for receipt of acceptances or renunciations</td>
<td>Not applicable</td>
</tr>
<tr>
<td>20</td>
<td>Names of any underwriters</td>
<td>Not applicable</td>
</tr>
<tr>
<td>21</td>
<td>Amount of any underwriting fee or commission</td>
<td>Not applicable</td>
</tr>
<tr>
<td>22</td>
<td>Names of any brokers to the issue</td>
<td>Not applicable</td>
</tr>
<tr>
<td>23</td>
<td>Fee or commission payable to the broker to the issue</td>
<td>Not applicable</td>
</tr>
<tr>
<td>24</td>
<td>Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of ‘security holders</td>
<td>Not applicable</td>
</tr>
<tr>
<td>25</td>
<td>If the issue is contingent on ‘security holders’ approval, the date of the meeting</td>
<td>Not applicable</td>
</tr>
<tr>
<td>26</td>
<td>Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled</td>
<td>Not applicable</td>
</tr>
<tr>
<td>27</td>
<td>If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders</td>
<td>Not applicable</td>
</tr>
<tr>
<td>28</td>
<td>Date rights trading will begin (if applicable)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>29</td>
<td>Date rights trading will end (if applicable)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>30</td>
<td>How do ‘security holders sell their entitlements in full through a broker?</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
31 How do security holders sell part of their entitlements through a broker and accept for the balance? Not applicable

32 How do security holders dispose of their entitlements (except by sale through a broker)? Not applicable

33 Despatch date Not applicable

Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities

34 Type of securities (tick one)
(a) Securities described in Part 1

(b) All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the securities are equity securities, the names of the 20 largest holders of the additional securities, and the number and percentage of additional securities held by those holders

36 If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional securities

+ See chapter 19 for defined terms.
Entities that have ticked box 34(b)

38 Number of securities for which quotation is sought
Not applicable

39 Class of securities for which quotation is sought
Not applicable

40 Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?
Not applicable

If the additional securities do not rank equally, please state:
• the date from which they do
• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now
Not applicable

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

42 Number and class of all securities quoted on ASX (including the securities in clause 38)
Not applicable

+ See chapter 19 for defined terms.
Quotation agreement

1. Quotation of our additional securities is in ASX’s absolute discretion. ASX may quote the securities on any conditions it decides.

2. We warrant the following to ASX.
   - The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
   - There is no reason why those securities should not be granted quotation.
   - An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

   Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty.

   - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.

   - We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the securities to be quoted, it has been provided at the time that we request that the securities be quoted.

   - If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3. We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4. We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before quotation of the securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ............................................................ Date: 30 September 2008
Chief Financial Officer

Print name: Mr Rob Turnbull

+ See chapter 19 for defined terms.